Swiss National Bank Makes New Investment in Septerna, Inc. $SEPN

Key Points

• The Swiss National Bank acquired 30,100 shares of Septerna, Inc. for approximately $174,000, bringing its ownership to 0.07% of the company.
• Septerna reported a quarterly loss of ($0.56) EPS, significantly missing analysts' expectations, and had revenue of only $0.12 million compared to an estimated $22.50 million.
• Multiple analysts have provided varying ratings for Septerna, with a mix of "buy," "sell," and "hold" ratings, and an average price target of $26.75 based on recent reports.

Swiss National Bank bought a new position in Septerna, Inc. (NASDAQ:SEPN - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 30,100 shares of the company's stock, valued at approximately $174,000. Swiss National Bank owned about 0.07% of Septerna as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. RA Capital Management L.P. purchased a new position in shares of Septerna during the 4th quarter valued at about $160,205,000. TRV GP VI LLC lifted its position in shares of Septerna by 33.6% during the 1st quarter. TRV GP VI LLC now owns 4,211,659 shares of the company's stock valued at $24,386,000 after buying an additional 1,059,203 shares in the last quarter. Samsara BioCapital LLC purchased a new position in shares of Septerna during the 4th quarter valued at about $63,399,000. Driehaus Capital Management LLC purchased a new position in shares of Septerna during the 4th quarter valued at about $59,301,000. Finally, BVF Inc. IL purchased a new position in shares of Septerna during the 4th quarter valued at about $56,151,000.

Analyst Ratings Changes

A number of research firms have recently weighed in on SEPN. Wells Fargo & Company lifted their price objective on Septerna from $11.00 to $18.00 and gave the company an "equal weight" rating in a research report on Friday, May 16th. HC Wainwright reaffirmed a "buy" rating and set a $26.00 price objective on shares of Septerna in a research report on Thursday, August 21st. Cantor Fitzgerald lifted their price objective on Septerna from $20.00 to $25.00 and gave the company an "overweight" rating in a research report on Friday, May 16th. Finally, Wall Street Zen cut Septerna from a "hold" rating to a "sell" rating in a research report on Saturday, August 16th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $26.75.

Septerna Trading Down 1.5%

SEPN traded down $0.18 on Monday, hitting $12.10. 197,661 shares of the company's stock traded hands, compared to its average volume of 230,640. The company's 50 day simple moving average is $11.83 and its 200-day simple moving average is $8.98. The firm has a market cap of $539.48 million and a price-to-earnings ratio of -1.20. Septerna, Inc. has a one year low of $4.17 and a one year high of $28.99.

Septerna (NASDAQ:SEPN - Get Free Report) last issued its earnings results on Monday, August 11th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.51). The business had revenue of $0.12 million for the quarter, compared to the consensus estimate of $22.50 million. Septerna had a negative net margin of 12,053.03% and a negative return on equity of 31.52%. As a group, equities analysts anticipate that Septerna, Inc. will post -7.11 EPS for the current fiscal year.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.